Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03644069Phase 2Unknown

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

Role: lead

NCT02528799Phase 1Completed

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

Role: lead

NCT03543540Phase 1Completed

Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease

Role: lead

NCT01932476Not ApplicableCompleted

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

Role: collaborator

All 4 trials loaded